HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Monoclonal Antibodies Targeting the IL-17/IL-17RA Axis: An Opportunity to Improve the Efficiency of Anti-VEGF Therapy in Fighting Metastatic Colorectal Cancer?

Abstract
Colorectal cancer is a major problem for public health worldwide because of its frequency and its severity. Many efforts have been carried to target the vascular endothelial growth factor (VEGF) pathway, one of the main promoters of pathological angiogenesis. Therapeutic monoclonal antibodies against VEGF have emerged as essential biopharmaceuticals for the advanced stages of the disease, in association with appropriate backbone chemotherapy. Unfortunately, after an initial benefit for the patients, resistance invariably develops. These mechanisms of resistance are largely studied and recent publications indicate that the interleukin (IL)-17/IL-17 receptor (IL-17R)A axis could be a key player in the pathological progression. In this mini review, we present evidence for IL-17A/IL-17RA axis targeting in colorectal cancer to improve efficiency of anti-VEGF therapy and to implement a new therapeutic strategy.
AuthorsSajida Ibrahim, Alban Girault, Marc Ohresser, Emilie Lereclus, Gilles Paintaud, Thierry Lecomte, William Raoul
JournalClinical colorectal cancer (Clin Colorectal Cancer) Vol. 17 Issue 1 Pg. e109-e113 (03 2018) ISSN: 1938-0674 [Electronic] United States
PMID29153431 (Publication Type: Journal Article, Review)
CopyrightCopyright © 2017 Elsevier Inc. All rights reserved.
Chemical References
  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Antineoplastic Agents, Immunological
  • IL17A protein, human
  • Interleukin-17
  • Receptors, Interleukin-17
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
Topics
  • Angiogenesis Inhibitors (pharmacology)
  • Animals
  • Antibodies, Monoclonal (therapeutic use)
  • Antineoplastic Agents, Immunological (pharmacology)
  • Colorectal Neoplasms (drug therapy)
  • Drug Resistance, Neoplasm (physiology)
  • Humans
  • Interleukin-17 (antagonists & inhibitors)
  • Receptors, Interleukin-17 (antagonists & inhibitors)
  • Vascular Endothelial Growth Factor A (antagonists & inhibitors)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: